MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$3,200K
EPS
$0.07
Unit: Thousand (K) dollars

Income Statement
2025-09-30
2024-12-31
2024-09-30
2024-06-30
Revenues
0 33* 42 57
Cost of revenue
0 37* 42 48
Gross profit
0 -4* 0 9
Research and development expense
1,643 655* 1,477 1,086
General and administrative expense
1,613 1,128* 1,544 1,088
Net expenses related to opko collaboration agreement
3,256 1,782* 3,021 2,174
Operating loss
-3,256 -1,786* -3,021 -2,165
Financial income, net
56 -2* -20
Income (loss) from continuing operations before income taxes, noncontrolling interest
--1,788* -3,021 -
Income tax expense (benefit)
-4* --
Net loss
-3,200 -1,792 -3,021 -2,145
Basic EPS
0.07 -0.047 0.08 0.06
Diluted EPS
0.07 -0.047 0.08 0.06
Basic Average Shares
47,089,814 38,215,765 37,644,612 37,090,160
Diluted Average Shares
47,089,814 38,215,765 37,644,612 37,090,160
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$3,200K (-5.93%↓ Y/Y)Financial income, net$56K Operating loss-$3,256K (-7.78%↓ Y/Y)Net expensesrelated to opko...$3,256K (7.78%↑ Y/Y)Research and developmentexpense$1,643K (11.24%↑ Y/Y)General andadministrative expense$1,613K (4.47%↑ Y/Y)

Entera Bio Ltd. (ENTX)

Entera Bio Ltd. (ENTX)